Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer

Table 1 Comparison of cytokines between MKN-45 and MKN-45P

	IL-1β(pg/mL)	IL-6 (pg/mL)	IL-8 (pg/mL)	VEGF (pg/mL)	MMP-2 (ng/mL)	TIMP-1 (ng/mL)
MKN-45	0.9 ± 0.7	1.2 ± 0.7	381.9 ± 147.1	1335.0 ± 624.3	0.3 ± 0.1	2.7 ± 1.8
MKN-45P	0.4 ± 0.2	2.9 ± 0.6	891.4 ± 210.2	3806.0 ± 229.8	0.7 ± 0.5	6.0 ± 4.0
P value	0.109	0.045	0.011	0.013	0.021	0.126

IL: Interleukin; VEGF: Vascular endothelial growth factor; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of metalloproteinase.

Table 2 Number of tumor nodules, volume of ascites, body weight, frequency of hydronephrosis and mitotic index in the mice treated with bevacizumab and the untreated mice

Treatment	n	Tumor nodules	Ascites (mL)	Body weight (g)	Hydronephrosis		Mitosis index
					Right kidney	Left kidney
Non-therapy	5	16.64 ± 5.061	0.60 ± 0.512	12.21 ± 0.513	4 (80)	2 (40)	21.0 ± 5.7b
Therapy	5	17.66 ± 3.45	0.04 ± 0.03	12.41 ± 0.61	2 (40)	1 (20)	9.6 ± 2.1

¹P = 0.783;

²P = 0.042;

³P = 0.591;

^bP < 0.01 vs therapy group.